Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018996497> ?p ?o ?g. }
- W2018996497 endingPage "90" @default.
- W2018996497 startingPage "84" @default.
- W2018996497 abstract "Purpose: To explore long-term immune responses after combined radio-gene-hormonal therapy. Methods and Materials: Thirty-three patients with prostate specific antigen 10 or higher or Gleason score of 7 or higher or clinical stage T2b to T3 were treated with gene therapy that consisted of 3 separate intraprostatic injections of AdHSV-tk on Days 0, 56, and 70. Each injection was followed by 2 weeks of valacyclovir. Intensity-modulated radiation therapy was delivered 2 days after the second AdHSV-tk injection for 7 weeks. Hormonal therapy was initiated on Day 0 and continued for 4 months or 2.3 years. Blood samples were taken before, during, and after treatment. Lymphocytes were analyzed by fluorescent antibody cell sorting (FACS). Results: Median follow-up was 26 months (range, 4–48 months). The mean percentages of DR+CD8+ T cells were increased at all timepoints up to 8 months. The mean percentages of DR+CD4+ T cells were increased later and sustained longer until 12 months. Long-term (2.3 years) use of hormonal therapy did not affect the percentage of any lymphocyte population. Conclusions: Sustained long-term (up to 8 to 12 months) systemic T-cell responses were noted after combined radio-gene-hormonal therapy for prostate cancer. Prolonged use of hormonal therapy does not suppress this response. These results suggest the potential for sustained activation of cell-mediated immune responses against cancer. Purpose: To explore long-term immune responses after combined radio-gene-hormonal therapy. Methods and Materials: Thirty-three patients with prostate specific antigen 10 or higher or Gleason score of 7 or higher or clinical stage T2b to T3 were treated with gene therapy that consisted of 3 separate intraprostatic injections of AdHSV-tk on Days 0, 56, and 70. Each injection was followed by 2 weeks of valacyclovir. Intensity-modulated radiation therapy was delivered 2 days after the second AdHSV-tk injection for 7 weeks. Hormonal therapy was initiated on Day 0 and continued for 4 months or 2.3 years. Blood samples were taken before, during, and after treatment. Lymphocytes were analyzed by fluorescent antibody cell sorting (FACS). Results: Median follow-up was 26 months (range, 4–48 months). The mean percentages of DR+CD8+ T cells were increased at all timepoints up to 8 months. The mean percentages of DR+CD4+ T cells were increased later and sustained longer until 12 months. Long-term (2.3 years) use of hormonal therapy did not affect the percentage of any lymphocyte population. Conclusions: Sustained long-term (up to 8 to 12 months) systemic T-cell responses were noted after combined radio-gene-hormonal therapy for prostate cancer. Prolonged use of hormonal therapy does not suppress this response. These results suggest the potential for sustained activation of cell-mediated immune responses against cancer. In reply to Dr. Millar et alInternational Journal of Radiation Oncology, Biology, PhysicsVol. 66Issue 5PreviewWe thank Dr. Millar et al. for their interest in our clinical study evaluating combined in situ adenoviral vector mediated HSV-tk genetherapy combined with radiotherapy and hormonal therapy for prostate cancer (1). We would like to point out that there is no chemotherapy in this trial. Sustained systemic T cell responses were noted. Full-Text PDF Alternative explanations for T-cell response to in-situ gene therapy for prostate cancer: In reply to Fugita et al. (Int J Radiat Oncol Biol Phys 2006;65:84–90)International Journal of Radiation Oncology, Biology, PhysicsVol. 66Issue 5PreviewWe read with great interest the recent article by Fujita et al. (1) on the combined usage of viral infection to gene target the prostate in prostate cancer patients together with radiation, chemotherapy, and hormonal therapy. The underlying hypothesis was that this would lead to an increase in circulating and prostate infiltrating T cells that may be recruited to help destroy the cancer cells. They report an early increase in CD8+ T cells and a later increase in CD4+ T cells. Full-Text PDF" @default.
- W2018996497 created "2016-06-24" @default.
- W2018996497 creator A5007266497 @default.
- W2018996497 creator A5024670184 @default.
- W2018996497 creator A5025245246 @default.
- W2018996497 creator A5037000397 @default.
- W2018996497 creator A5040799018 @default.
- W2018996497 creator A5041990261 @default.
- W2018996497 creator A5042000405 @default.
- W2018996497 creator A5065048363 @default.
- W2018996497 creator A5080482111 @default.
- W2018996497 creator A5086586078 @default.
- W2018996497 creator A5088580819 @default.
- W2018996497 date "2006-05-01" @default.
- W2018996497 modified "2023-10-18" @default.
- W2018996497 title "Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients" @default.
- W2018996497 cites W1414585854 @default.
- W2018996497 cites W1910139999 @default.
- W2018996497 cites W1964969453 @default.
- W2018996497 cites W1972601062 @default.
- W2018996497 cites W1974190682 @default.
- W2018996497 cites W1976501204 @default.
- W2018996497 cites W2000886560 @default.
- W2018996497 cites W2009068566 @default.
- W2018996497 cites W2012315955 @default.
- W2018996497 cites W2013474978 @default.
- W2018996497 cites W2014180431 @default.
- W2018996497 cites W2015255922 @default.
- W2018996497 cites W2015597117 @default.
- W2018996497 cites W2018445655 @default.
- W2018996497 cites W2019378587 @default.
- W2018996497 cites W2019644784 @default.
- W2018996497 cites W2020356718 @default.
- W2018996497 cites W2024356087 @default.
- W2018996497 cites W2040091965 @default.
- W2018996497 cites W2047683079 @default.
- W2018996497 cites W2051621257 @default.
- W2018996497 cites W2054125735 @default.
- W2018996497 cites W2056643793 @default.
- W2018996497 cites W2058680827 @default.
- W2018996497 cites W2062592944 @default.
- W2018996497 cites W2074421032 @default.
- W2018996497 cites W2075718053 @default.
- W2018996497 cites W2076959899 @default.
- W2018996497 cites W2078162122 @default.
- W2018996497 cites W2080439368 @default.
- W2018996497 cites W2082297197 @default.
- W2018996497 cites W2083314535 @default.
- W2018996497 cites W2085834739 @default.
- W2018996497 cites W2087939292 @default.
- W2018996497 cites W2089006089 @default.
- W2018996497 cites W2089751686 @default.
- W2018996497 cites W2094315815 @default.
- W2018996497 cites W2095229531 @default.
- W2018996497 cites W2102217966 @default.
- W2018996497 cites W2102748669 @default.
- W2018996497 cites W2114214906 @default.
- W2018996497 cites W2128365260 @default.
- W2018996497 cites W2130559643 @default.
- W2018996497 cites W2131098994 @default.
- W2018996497 cites W2134766389 @default.
- W2018996497 cites W2137900501 @default.
- W2018996497 cites W2138608959 @default.
- W2018996497 cites W2144498681 @default.
- W2018996497 cites W2145626748 @default.
- W2018996497 cites W2145829662 @default.
- W2018996497 cites W2153674426 @default.
- W2018996497 cites W2163120057 @default.
- W2018996497 cites W2167919463 @default.
- W2018996497 cites W2172038823 @default.
- W2018996497 cites W2316095838 @default.
- W2018996497 cites W2334127382 @default.
- W2018996497 cites W2413099559 @default.
- W2018996497 doi "https://doi.org/10.1016/j.ijrobp.2005.11.009" @default.
- W2018996497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16472937" @default.
- W2018996497 hasPublicationYear "2006" @default.
- W2018996497 type Work @default.
- W2018996497 sameAs 2018996497 @default.
- W2018996497 citedByCount "39" @default.
- W2018996497 countsByYear W20189964972012 @default.
- W2018996497 countsByYear W20189964972013 @default.
- W2018996497 countsByYear W20189964972014 @default.
- W2018996497 countsByYear W20189964972015 @default.
- W2018996497 countsByYear W20189964972016 @default.
- W2018996497 countsByYear W20189964972017 @default.
- W2018996497 countsByYear W20189964972018 @default.
- W2018996497 countsByYear W20189964972019 @default.
- W2018996497 countsByYear W20189964972020 @default.
- W2018996497 countsByYear W20189964972021 @default.
- W2018996497 countsByYear W20189964972022 @default.
- W2018996497 crossrefType "journal-article" @default.
- W2018996497 hasAuthorship W2018996497A5007266497 @default.
- W2018996497 hasAuthorship W2018996497A5024670184 @default.
- W2018996497 hasAuthorship W2018996497A5025245246 @default.
- W2018996497 hasAuthorship W2018996497A5037000397 @default.
- W2018996497 hasAuthorship W2018996497A5040799018 @default.
- W2018996497 hasAuthorship W2018996497A5041990261 @default.
- W2018996497 hasAuthorship W2018996497A5042000405 @default.